HBOT for Cancer Patients: Can Hyperbaric Oxygen Treatment Support Recovery?
- HBOT UK
- Jul 14
- 14 min read
Cancer remains one of the leading causes of illness and death in the UK, with hundreds of thousands of new registrations reported each year in national cancer statistics. More people are living longer with and beyond cancer, often experiencing late effects from radiotherapy and surgery. In this context, HBOT for cancer is increasingly discussed as a way to support recovery from radiation injury and complex wounds, rather than as a primary anti‑cancer cure.
Hyperbaric oxygen treatment is not an approved primary cancer treatment, but current evidence suggests it can be a useful adjunct for selected patients - mainly to help heal late radiation tissue injury and complex wounds after cancer therapy - without accelerating tumor growth or recurrence. Research into hbot cancer treatment is ongoing and larger clinical trials are still needed.
This article explains what cancer is, how hyperbaric oxygen therapy for cancer patients may work mechanistically, how hyperbaric oxygen treatment is currently used around cancer care, what the research shows, safety considerations, and key questions patients commonly ask. It focuses on UK and European guidance and does not offer treatment recommendations - HBOT protocols described here are from research settings only.
Medical Disclaimer: This article is for general informational and educational purposes only. It does not constitute medical advice. Always consult a qualified GP or healthcare professional before considering HBOT, particularly if you have any pre-existing medical conditions, are pregnant, or are undergoing medical treatment.
Table of Contents
1. What Is Cancer?
Cancer is a group of malignant diseases where cells grow and divide in an uncontrolled way, can invade nearby tissues, and sometimes spread (metastasise) to other parts of the body. These changes usually begin when genetic damage disrupts normal checks on cell growth and repair. Different cancers - for example breast, lung, prostate, brain and blood cancers - behave differently, but share this fundamental problem of uncontrolled growth.
In the UK, NHS England and the National Disease Registration Service report high annual cancer incidence, with many people living with long‑term consequences of treatment. These data underpin planning for services that must address both initial cancer care and survivorship issues such as chronic radiation injury.
A key feature of many solid tumors is tumor hypoxia - regions inside the tumor with very low oxygen levels. Hypoxic tumor cells tend to be more resistant to radiotherapy and chemotherapy, more likely to metastasise, and associated with poorer prognosis.
Cancer Pathophysiology in Plain Language
Inside a solid tumor, rapidly dividing cancer cells can outgrow their blood supply, creating areas with low oxygen, acidity and poor perfusion. Cancer cells adapt by changing how they generate energy, remodelling surrounding tissue and recruiting abnormal blood vessels.
These adaptations help tumor cells survive but make them harder to kill with standard treatments. Hypoxic cells can be several times more resistant to radiation because radiation damage to DNA is fixed more effectively when oxygen is present.
Common Treatment Pathways and Late Effects
Most patients with breast, lung, prostate, brain and blood cancers will receive combinations of surgery, radiotherapy, chemotherapy, targeted therapies or immunotherapy, depending on stage and biology. Although these treatments can be effective, they may leave late effects such as radiation tissue injury in the head and neck, pelvis, breast or brain, and chronic non‑healing wounds.
UK charities and NHS guidance increasingly highlight cancer survivorship - living with and beyond cancer - and the need to manage long‑term side effects as part of comprehensive cancer care.
2. How Does Hyperbaric Oxygen Therapy Work?
Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen at pressures higher than normal atmospheric pressure, typically between 1.5 and 3.0 atmospheres absolute (ATA) in a sealed chamber. Under these conditions, far more oxygen dissolves in blood plasma, so tissue oxygen levels can increase markedly for 15-60 minutes after a session.
Hyperbaric oxygen treatment has long been used for disorders involving severe hypoxia or tissue damage, including decompression sickness, carbon monoxide poisoning, non‑healing diabetic wounds and delayed radiation tissue injury. In oncology, clinicians and researchers mainly explore HBOT for radiotherapy and surgery as an adjunct - either to radiosensitise tumours or to promote healing in damaged normal tissues.
Oxygen and Tumor Hypoxia
A major rationale for HBOT cancer cells research is temporarily reversing tumor hypoxia. Experimental and clinical studies show HBOT can raise oxygen partial pressure within tumors from very low values to higher levels for a limited period.
In theory, this increased oxygen can:
Enhance radiation‑induced DNA damage in tumor cells (radiosensitisation).
Improve chemotherapy delivery into poorly perfused regions.
Reduce selection pressure for aggressive, hypoxia‑adapted clones.
A 2025 review in Frontiers in Oncology described how HBOT re‑oxygenates the tumor microenvironment and may improve progression‑free survival in early-phase glioblastoma studies when combined with radiotherapy and modern biotechnologies. [7]
Oxygen, Reactive Oxygen Species and Cancer Cell Death
HBOT increases reactive oxygen species (ROS), and several mechanistic papers suggest ROS can damage tumor cells when exposure is carefully controlled. A pharmacology review in Biomedicine & Pharmacotherapy explained how HBOT can modulate oxidative stress, ferroptosis, and cancer stem cell behaviour, potentially enhancing chemotherapy and immunotherapy in hypoxic tumors. [9]
These mechanisms help explain how oxygen plays a critical role in killing cancer cells, but they do not mean HBOT is a proven standalone anti‑cancer therapy. Most authors emphasise that HBOT should be viewed as an adjunct in carefully designed treatment regimens.
How HBOT Affects Normal Tissues
Hyperbaric oxygen treatment can stimulate angiogenesis (growth of new blood vessels), support collagen synthesis and bone repair, and reduce chronic inflammation in poorly perfused tissues. In delayed radiation injury, HBOT appears to improve blood supply, reduce fibrosis and support stem‑cell‑mediated tissue regeneration.
These effects explain why hyperbaric oxygen therapy cancer risk discussions now focus on safety rather than tumour stimulation - HBOT is recognised for delayed radiation injury and complex wounds, not as a primary cancer control strategy. [3]
3. HBOT and Cancer: What the Research Shows
UHMS and NHS Recognition Status
The Undersea and Hyperbaric Medical Society (UHMS) indications manual lists conditions for which HBOT is an established indication in formal clinical settings. Cancer itself - as a primary malignancy - is not listed as an approved HBOT indication. [5]
However, UHMS recognises delayed radiation injury (soft tissue and bony necrosis) as an established indication, reflecting substantial evidence that HBOT can help heal radiation‑damaged tissues. In practice, many HBOT for cancer patients referrals relate to head and neck osteoradionecrosis, pelvic haemorrhagic cystitis after prostate radiotherapy, or complex wounds in previously irradiated fields.
NHS England’s service specification for hyperbaric oxygen therapy commissions HBOT nationally for a limited set of indications – mainly decompression illness and certain acute emergencies - and does not include routine use for primary malignancy. Cancer‑related referrals typically concern severe late radiation tissue injury or non‑healing wounds in carefully selected patients. [13]
Research into HBOT for cancer represents an area of active clinical investigation. This is not a UHMS‑recognised primary indication - the evidence continues to develop, and larger trials are ongoing.
Positive Findings
A 2023 Cochrane review evaluated HBOT for late radiation tissue injury, including head and neck, bladder and rectal complications. HBOT at 2.0-2.5 ATA was associated with improved symptom relief, reduced wound breakdown in irradiated surgical fields, and better pain outcomes, although sample sizes were modest and study quality varied. [6]
A 2025 systematic review of HBOT for chronic radiotherapy‑related adverse effects in head and neck cancer reported beneficial effects in most of 17 studies (640 patients), particularly for osteoradionecrosis and oral health, with low rates of serious adverse events. [11]
A 2025 safety evaluation in Medicina followed 45 patients with active or previously treated solid tumors who underwent HBOT mainly for late radiation necrosis and post‑surgical wound problems. Over a median follow‑up of 783 days, 59.5% had no recurrence, 8.7% had recurrence, and 2.7% had persistent disease - with no significant link between HBOT session number and metastasis or mortality, and no HBOT‑related serious complications observed. [2]
These studies underpin the idea of using hyperbaric oxygen therapy for cancer patients to support healing of radiation injury and complex wounds - rather than as direct cancer recovery therapy targeting tumour cells.
Mixed and Null Results: Tumour Control and Survival
Concerns that HBOT might “feed” cancer have been addressed in several reviews. A 2003 review in Undersea and Hyperbaric Medicine concluded that in vitro, in vivo and clinical data strongly suggest no more than a neutral effect of HBOT on tumour growth, with some evidence of inhibitory effects. [3]
A 2012 review, “Hyperbaric oxygen therapy and cancer - a review”, reached similar conclusions, finding no systematic promotion of malignancy. [1]
More recent work reviewing hyperbaric oxygen therapy and radiotherapy describes promising activity in mitigating late toxicities, particularly pelvic haemorrhagic cystitis, but notes that the radiosensitising role of HBOT remains speculative and that evidence is heterogeneous and often low quality. [10]
Randomised trials combining HBOT with radiotherapy in head and neck and cervical cancers sometimes show improved local control, but often no clear survival advantage and logistical or toxicity challenges. As a result, this combined approach is not widely adopted in routine oncology practice.
Taken together, these findings suggest that hyperbaric oxygen cancer concerns about tumour promotion are not supported by available data, while potential anti‑tumour or radiosensitising benefits remain under active investigation.
Evidence Note: Taken together, these findings suggest that hyperbaric oxygen cancer concerns about tumour promotion are not supported by available data, while potential anti‑tumour or radiosensitising benefits remain under active investigation.
Preclinical Work: Oxygen Killing Cancer Cells
Experimental models provide additional insight into HBOT cancer cells biology:
A xenograft study using A549 non‑small cell lung cancer cells in mice found that HBOT at 2.5 ATA for 90 minutes once daily, 5 days per week for 2 weeks improved tumour oxygenation and was associated with suppressed tumour growth, increased necrosis and apoptosis. [8]
Earlier rat mammary tumour studies showed that HBOT alone or combined with 5‑fluorouracil attenuated growth in certain models.
Mechanistic work suggests HBOT may enhance immunotherapy and chemotherapy by alleviating hypoxia‑driven resistance.
These experiments support the idea that oxygen and ROS can damage cancer cells, but translation into routine practice - including HBOT for breast cancer, HBOT for lung cancer, HBOT for prostate cancer, HBOT for brain cancer and other types - remains limited and highly context‑specific.
Current and Ongoing Clinical Trials
Several modern trials explore HBOT as part of multimodal cancer regimens:
Phase II glioma and glioblastoma studies combine HBOT with temozolomide and radiotherapy, sometimes described as hbot for brain cancer, using around 2.5 ATA for 90 minutes, 5 sessions per week and reporting improved progression‑free survival in small cohorts.[7]
Trials examine HBOT alongside radiotherapy and chemotherapy in other solid tumours, including breast and pelvic cancers, with mixed results on tumour control but more consistent improvements in late toxicity.[12]
Emerging research considers HBOT with nanomedicine, immunotherapy and hyperbaric oxygen therapy and chemotherapy combinations to overcome hypoxia‑driven resistance.[9]
Overall, HBOT for cancer treatment is best described as an investigational adjunct, particularly for managing late radiation effects, rather than a proven primary cancer therapy.
4. Treatment Protocols Used in Research
Published trials and case series report a range of HBOT protocols in oncology‑related settings. These HBOT protocols for cancer examples are research protocols, not treatment advice.
Typical parameters include:
Pressure - usually 2.0-2.5 ATA, occasionally up to 3.0 ATA in multiplace chambers.
Session duration - commonly 60–90 minutes of oxygen breathing per session.
Frequency - once daily, 5 days per week for several weeks.
Total sessions - frequently between 20 and 40 treatments for chronic radiation injury, and 10-20 sessions in some wound‑healing protocols.
In the A549 lung cancer xenograft model often cited in HBOT for lung cancer discussions, HBOT was delivered at 2.5 ATA, 90 minutes per session, once daily, 5 days per week over 2 weeks, starting 45 days after tumour injection.[8]
In late radiation tissue injury after head and neck or pelvic radiotherapy – relevant to HBOT therapy for breast cancer and HBOT for prostate cancer - HBOT is typically used at 2.0-2.5 ATA for about 90 minutes, with 30-40 treatments.[11][12]
These patterns underpin common questions about how many HBOT sessions for cancer‑related complications have been studied, even though exact numbers vary by indication and study design.
5. Safety Considerations and Contraindications
HBOT has a well‑described safety profile, but it is not risk‑free. Reviews of HBOT around radiotherapy highlight both benefits and adverse events.
Common Side Effects
Reported side effects include:
Middle ear barotrauma - ear pain or eardrum injury from pressure changes.
Temporary visual changes - reversible myopia or blurred vision.
Oxygen toxicity seizures - rare but serious, especially at higher pressures or longer exposures.
Fatigue, claustrophobia and sinus pain - usually mild and self‑limiting.
Absolute and Relative Contraindications
Absolute contraindications generally include:
Untreated tension pneumothorax.
Certain untreated severe obstructive lung diseases with high risk of air trapping.
Relative contraindications often include:
Poorly controlled epilepsy.
Severe COPD with bullous changes.
Recent ear surgery or inability to equalise ear pressure.
Some chemotherapeutic agents with known oxygen toxicity interactions (for example, bleomycin), requiring careful timing.
In oncology, a history of malignancy itself is not considered a contraindication to HBOT in modern practice surveys, provided there is a clear indication and careful risk–benefit assessment.[1]
Patients and clinicians often discuss hyperbaric oxygen therapy cancer risk, especially whether oxygen could “feed” tumours. Current evidence suggests HBOT has neutral or inhibitory effects on tumour growth when used appropriately and does not systematically increase recurrence or metastasis.[2][3]
This article is for general informational and educational purposes only. It does not constitute medical advice. Hyperbaric oxygen chambers supplied by Hyperbaric Oxygen Treatment UK are wellness and professional equipment, not MHRA-regulated medical devices for the treatment of disease. Always consult a qualified GP or healthcare professional before considering HBOT, particularly if you have any pre-existing medical conditions, are pregnant, or are undergoing medical treatment.
6. Who Is Currently Exploring HBOT for Cancer?
Work on HBOT for cancer patients is mainly driven by:
Hyperbaric medicine units in large hospitals, focusing on radiation injury, complex wounds and carefully selected adjunctive protocols.
Oncology teams running early‑phase trials combining HBOT with radiotherapy, chemotherapy or immunotherapy in glioma, breast and pelvic cancers.
Academic groups studying tumour hypoxia, ROS biology and matrix changes under HBOT.
In the UK and Europe, oxygen therapy for cancer UK practice distinguishes clearly between MHRA‑regulated medical uses and wellness contexts. HBOT for malignancy remains concentrated in specialist centres and research settings, with NHS commissioning focused on established indications such as decompression illness and severe radiation necrosis.
People also ask if cancer patients can use a hyperbaric chamber or HBOT chamber for cancer at home. Home or wellness‑grade chambers are available, but any use should be discussed with a GP or oncology team.
7. Frequently Asked Questions About HBOT for Cancer Patients
Q. Is HBOT an approved treatment for cancer?
A. HBOT is not an approved primary anti‑cancer treatment, but it is an established indication for delayed radiation tissue injury and selected complex wounds in people who may have or have had cancer. Research into HBOT cancer treatment remains investigational and focuses on adjunctive roles, not replacement of standard therapies.[5]
Q. What does the research say about HBOT for cancer?
A. Overall, research suggests HBOT is safe as an adjunct in patients with solid tumours and can improve radiation‑related complications, with neutral or inhibitory effects on tumour progression. Tumour control data are mixed, and no strong evidence supports HBOT as a standalone anti‑cancer therapy.[2][10]
Q. What pressure levels are used in research for cancer?
A. Most oncology‑related HBOT studies use 2.0-2.5 ATA, with session durations of 60-90 minutes. Some protocols for complex radiation injury or experimental radiosensitisation extend towards 3.0 ATA in carefully monitored settings.[6]
Q. How many HBOT sessions for cancer have been studied?
A. For late radiation tissue injury, trials commonly use 20-40 sessions, delivered once daily, 5 days per week. Preclinical cancer models and early glioma studies sometimes use 10-20 sessions or more, linked to radiotherapy or chemotherapy cycles.[7][11]
Q. Is HBOT safe for cancer patients?
A. Patients often ask, “Is HBOT safe for cancer patients?” Reviews indicate HBOT is generally safe and well tolerated when used for appropriate indications, with most side effects being reversible visual changes, middle ear barotrauma and rare oxygen‑toxicity seizures. There is no strong evidence that HBOT increases tumour growth or metastasis when used correctly.[2][3]
Q. Is HBOT available on the NHS for cancer?
A. NHS England commissions HBOT for a limited set of indications, mainly decompression illness and certain acute emergencies; routine HBOT for primary cancer treatment is not included. Some cancer patients may receive HBOT for NHS‑funded management of severe late radiation tissue injury or complex wounds.[13]
Q. Can HBOT be used at home for cancer?
A. Home or wellness‑grade hyperbaric chambers are not MHRA‑regulated medical devices for the treatment of disease. 2.0 and 2.5 ATA chambers can replicate research protocols used in hospital‑based oncology. Any use should be discussed with a GP or oncology team.
Q. What should I ask my doctor before trying HBOT?
A. You should ask:
Whether HBOT is appropriate for your specific situation (for example, radiation injury versus active tumour).
How HBOT might interact with your chemotherapy, radiotherapy or other medications, including hyperbaric oxygen therapy and chemotherapy combinations.
What risks and benefits apply given your lung function, ear health and overall medical history.
You can also ask whether your case might be considered for a clinical trial, since much HBOT for cancer recovery work remains investigational.
Q. Does oxygen kill cancer cells?
A. People sometimes ask “does oxygen kill cancer cells” or “does oxygen destroy cancer cells”. Laboratory models show that higher oxygen and ROS levels can trigger cancer cell death and suppress growth under carefully controlled HBOT exposures. However, cancer is complex, and oxygen alone is not a cure; oxygen‑based strategies are being explored mainly as adjuncts to standard treatments.[8][9]
Q. Can oxygen help lung cancer?
A. Preclinical studies indicate “can oxygen help lung cancer” is partly true in models: HBOT improved tumour oxygenation and suppressed growth in A549 lung cancer xenografts. Clinical evidence remains limited, and patients with lung cancer may have fragile lungs, so any HBOT use needs specialist evaluation.[8]
8. Summary of Current Evidence
Overall, current data indicate that hyperbaric oxygen treatment for cancer patients is best understood as an adjunct in two main areas: healing late radiation tissue injury and supporting recovery from complex surgery and wounds. Cochrane and other systematic reviews support HBOT for delayed radiation injury, with improvements in tissue healing and symptom control but no clear short‑term survival advantage.[6][12]
Preclinical and early clinical work suggests HBOT can reverse tumour hypoxia, increase ROS and improve radiosensitisation and drug delivery, with promising results in glioma, head and neck and pelvic cancers - yet evidence remains small‑scale and heterogeneous. Importantly, multiple reviews have found no strong evidence that HBOT promotes cancer growth or recurrence when used appropriately, and a history of malignancy is not considered a contraindication when there is a clear indication such as radiation injury.[1][3]
For now, HBOT for cancer recovery and other forms of cancer recovery therapy involving HBOT should be viewed as evolving areas of supportive care and clinical investigation, not as replacements for established oncology treatments. The Undersea and Hyperbaric Medical Society recognises delayed radiation injury - not primary malignancy - as an established indication, and NHS England commissioning reflects this distinction. Larger, well‑designed trials are needed to clarify which cancer types, stages and HBOT protocols provide the most benefit and to define long‑term safety and cost‑effectiveness.
Medical Disclaimer: This article is for general informational and educational purposes only. It does not constitute medical advice. Hyperbaric oxygen chambers supplied by Hyperbaric Oxygen Treatment UK are wellness and professional equipment, not MHRA-regulated medical devices for the treatment of disease. Always consult a qualified GP or healthcare professional before considering HBOT, particularly if you have any pre-existing medical conditions, are pregnant, or are undergoing medical treatment.
This research review is published by Hyperbaric Oxygen Treatment UK, a specialist hyperbaric chamber supplier and installer based in Cleveleys, Lancashire, UK, with 120+ chamber installations across the UK, Europe, and internationally. Member of the International Board of Undersea Medicine (IBUM) and the International Hyperbarics Association (IHA). Information about available HBOT equipment for clinical and home environments can be found at hyperbaricoxygentreatment.uk.
9. References & Medical Sources
Moen I, Stuhr L.E.B. “Hyperbaric Oxygen Therapy and Cancer-A Review.” Journal of Cancer, 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3510426/
Costa D.A. et al. “Hyperbaric Oxygen Therapy for Managing Cancer Treatment Complications in Patients with Solid Tumors.” Medicina (Kaunas), 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943617/
Bennett M.H. et al. “Hyperbaric Oxygen: Does It Promote Growth or Recurrence of Malignancy?” Undersea and Hyperbaric Medicine, 2003. https://pubmed.ncbi.nlm.nih.gov/12841604/
Feldmeier J.J. et al. “Does Hyperbaric Oxygen Have a Cancer‑Causing or ‑Promoting Effect? A Review of the Pertinent Literature.” Undersea and Hyperbaric Medicine, 1994. https://pubmed.ncbi.nlm.nih.gov/8000286/
Undersea and Hyperbaric Medical Society (UHMS). “HBO2 Therapy Indications.” UHMS Indications Manual and online resource. https://uhms.org/resources/featured-resources/hbo-indications.html
Lin Z.C. et al. “Hyperbaric Oxygen Therapy for Late Radiation Tissue Injury.” Cochrane Database of Systematic Reviews, 2023; CD005005. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005005.pub5/full
Mei S. et al. “Exploring a New Direction in Targeted Cancer Therapy Through Hyperbaric Oxygen Therapy Combined with Biomedical Engineering Techniques.” Frontiers in Oncology, 2025. https://www.frontiersin.org/articles/10.3389/fonc.2025.1580515/full
Hsu H. et al. “Hyperbaric Oxygen Suppressed Tumor Progression Through Regulating Apoptosis and Angiogenesis in Lung Cancer.” Scientific Reports, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8187442/
Advances and Challenges of Hyperbaric Oxygen Therapy in Cancer Therapy.” Biomedicine & Pharmacotherapy, 2025. https://pubmed.ncbi.nlm.nih.gov/41172962/
“The Elusive Evidence on Hyperbaric Oxygen Therapy and Radiotherapy.” Radiotherapy and Oncology, 2026. https://pubmed.ncbi.nlm.nih.gov/41627499/
“Hyperbaric Oxygen Therapy for Late Radiation Tissue Toxicity Injury After Head and Neck Cancer: A Systematic Review of the Literature.” Head & Neck, 2025. https://pubmed.ncbi.nlm.nih.gov/41044659/
“Hyperbaric Oxygen Therapy for Chronic Radiotherapy‑Related Adverse Effects.” Medical Gas Research, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12700310/
NHS England. “Service Specification: Hyperbaric Oxygen Therapy (All Ages).” 2018, updated. https://www.england.nhs.uk/publication/service-specification-hyperbaric-oxygen-therapy-all-ages/
National Disease Registration Service. “Cancer Registration Statistics, England, 2022.” NHS England Digital, 2024. https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2022
Cochrane Editorial Team. “Hyperbaric Oxygen Therapy for the Treatment of the Late Effects of Radiotherapy – Plain Language Summary.” 2023. https://www.cochrane.org/evidence/CD005005_hyperbaric-oxygen-therapy-treatment-late-effects-radiotherapy
Comments